Schrodinger, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
SDGR
Schrodinger, INCSchrodinger, Inc. reported a 23% increase in total revenue to $255.9 million and significantly reduced its net loss to $103.3 million in 2025, driven by robust software sales and drug discovery collaborations, despite discontinuing a key clinical program.
NASDAQ
SDGR
Schrodinger, INC10-K: Schrodinger, Inc. Reports Full Year 2024 Results, Highlights Progress in Drug Discovery Programs
Schrodinger, Inc. reports its full year 2024 financial results, showcasing growth in software revenue and advancements in its collaborative and proprietary drug discovery programs.
NASDAQ
SDGR
Schrodinger, INC10-K: Schrdinger, Inc. Reports Full Year 2023 Results, Highlights Growth in Software and Drug Discovery
Schrdinger, Inc. announces its full year 2023 financial results, showcasing a 20% increase in total revenue and a net income of $40.7 million.